Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Prostate Cancer Diagnostic Included in NCCN Early Detection Guidelines

NEW YORK (GenomeWeb) – MDxHealth announced today that its ConfirmMDx for Prostate Cancer screening test has been included in the US 2016 National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer screening.

"Tests that improve specificity in the post-biopsy state — including 4Kscore, PHI, percent free PSA, PCA3, and ConfirmMDx — should be considered in patients thought to be higher risk despite a negative prostate biopsy," the NCCN guidelines now say.

ConfirmMDx is an epigenetic tissue-based test, and provides a negative predictive value of 90 percent for all prostate cancers, and 96 percent for clinically significant prostate cancers, the company said. The test results can also help guide repeat prostate biopsies.

In 2013, the NCCN also included MDxHealth's PredictMDx for Glioblastoma test in its guidelines for gauging MGMT methylation status in central nervous system cancers.

"Inclusion in the guidelines establishes ConfirmMDx as a 'standard of care' for the management of men at risk for undetected prostate cancer," said CEO Jan Groen in a statement. "This is the second MDxHealth test to be included in the NCCN guidelines, with PredictMDx for Glioblastoma added in 2013, and illustrates our commitment to delivering clinically valuable solutions to improve patient outcomes."